A number of products have passed the scientific and technological achievement appraisal, entered the clinic, and pioneered in China. They have been identified as having high technical barriers and are at the international leading level.

In 2019, R&L Medical was evaluated as a key recommended enterprise and received 10 million RMB of government subsidy support; in 2020, R&L Medical was recognized as a high-tech R&D center by Hangzhou Government, and was awarded the title of "Eagle Plan" , and as one of the five enterprises, it represented Zhejiang Province to participate in the National Innovation Activity in 2020. With the development of the company, we also continue to receive attention of innovation capital, and has already completed the angel round and the A round financing in 2019 and 2021 respectively,reserving sufficient power for future sustainable development.

R&L Medical starts from the wound field but will not be limited to the wound business. We will rely on our existing technology reserves, expand our product portfolio around related therapies, continue to build a platform-oriented enterprise, and continuously increase our own hematopoietic function and anti-risk capacity, and strive to realize our grand dream of building a Chinese version of Johnson & Johnson Medical!

Talent first is the development concept we have always adhered to. We stick to our own unique values and long term planning, continue to attract like-minded entrepreneurial partners to polish high-tech medical technology and develop innovative business models; to learn and practice together to achieve our ambitious vision of leading medical technology and contributing to the world.

R & L Medical - High-End Wound Care Material